Wendy Jane Noble

List of Publications by Year
in descending order

90 papers	9,457 citations	81743 39 h-index	69108 77 g-index
99 all docs	99 docs citations	99 times ranked	11319 citing authors

#	Article	IF	Citations
1	Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy. New England Journal of Medicine, 1999, 341, 468-475.	13.9	1,256
2	Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends in Molecular Medicine, 2009, 15, 112-119.	3.5	778
3	Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 6990-6995.	3.3	649
4	Roles of tau protein in health and disease. Acta Neuropathologica, 2017, 133, 665-704.	3.9	639
5	Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Reports, 2013, 14, 389-394.	2.0	510
6	Cdk5 Is a Key Factor in Tau Aggregation and Tangle Formation In Vivo. Neuron, 2003, 38, 555-565.	3.8	474
7	The Importance of Tau Phosphorylation for Neurodegenerative Diseases. Frontiers in Neurology, 2013, 4, 83.	1.1	312
8	Astrocytes are important mediators of AÎ²-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death and Disease, 2011, 2, e167-e167.	2.7	304
9	The ER-Mitochondria Tethering Complex VAPB-PTPIP51 Regulates Autophagy. Current Biology, 2017, 27, 371-385.	1.8	287
10	Î±-Synuclein binds to the ERâ€“mitochondria tethering protein VAPB to disrupt Ca2+ homeostasis and mitochondrial ATP production. Acta Neuropathologica, 2017, 134, 129-149.	3.9	262
11	<scp>ALS</scp> / <scp>FTD</scp> â€associated <scp>FUS</scp> activates <scp>GSK</scp> â€3Î² to disrupt the <scp>VAPB</scp> â€“ <scp>PTPIP</scp> 51 interaction and <scp>ER</scp> â€“mitochondria associations. EMBO Reports, 2016, 17, 1326-1342.	2.0	201
12	Clusterin regulates Î²-amyloid toxicity via Dickkopf-1-driven induction of the wntâ€“PCPâ€“JNK pathway. Molecular Psychiatry, 2014, 19, 88-98.	4.1	197
13	Presenilin Redistribution Associated with Aberrant Cholesterol Transport Enhances Î²-Amyloid Production<i>In Vivo</i>. Journal of Neuroscience, 2003, 23, 5645-5649.	1.7	170
14	Tyrosine 394 Is Phosphorylated in Alzheimer's Paired Helical Filament Tau and in Fetal Tau with c-Abl as the Candidate Tyrosine Kinase. Journal of Neuroscience, 2005, 25, 6584-6593.	1.7	168
15	A role for tau at the synapse in Alzheimer's disease pathogenesis. Neuropharmacology, 2014, 76, 1-8.	2.0	160
16	Collapsin response mediator proteinâ€2 hyperphosphorylation is an early event in Alzheimerâ€™s disease progression. Journal of Neurochemistry, 2007, 103, 1132-1144.	2.1	158
17	Molecular motors implicated in the axonal transport of tau and Î±-synuclein. Journal of Cell Science, 2005, 118, 4645-4654.	1.2	141
18	Tau phosphorylation affects its axonal transport and degradation. Neurobiology of Aging, 2013, 34, 2146-2157.	1.5	136

#	Article	IF	Citations
19	Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiology of Aging, 2012, 33, 431.e27-431.e38.	1.5	117
20	Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. FASEB Journal, 2009, 23, 739-750.	0.2	113
21	Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease. JAMA Neurology, 2020, 77, 164.	4.5	113
22	Co-localization of cholesterol, apolipoprotein E and fibrillar Aî² in amyloid plaques. Molecular Brain Research, 2003, 110, 119-125.	2.5	108
23	Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimerâ€™s disease. PLoS Genetics, 2017, 13, e1006593.	1.5	102
24	Calsyntenin-1 mediates axonal transport of the amyloid precursor protein and regulates AÂ production. Human Molecular Genetics, 2012, 21, 2845-2854.	1.4	100
25	Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimerâ€™s disease brain. Acta Neuropathologica Communications, 2016, 4, 34.	2.4	100
26	Anti-Inflammatory Impact of Minocycline in a Mouse Model of Tauopathy. Frontiers in Psychiatry, 2010, 1, 136.	1.3	91
27	The VAPB-PTPIP51 endoplasmic reticulum-mitochondria tethering proteins are present in neuronal synapses and regulate synaptic activity. Acta Neuropathologica Communications, 2019, 7, 35.	2.4	88
28	Mediators of tau phosphorylation in the pathogenesis of Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2009, 9, 1647-1666.	1.4	82
29	Functional Implications of Glycogen Synthase Kinase-3-Mediated Tau Phosphorylation. International Journal of Alzheimer's Disease, 2011, 2011, 1-11.	1.1	82
30	Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau. FEBS Journal, 2011, 278, 2927-2937.	2.2	78
31	Astrocytes and neuroinflammation in Alzheimer's disease. Biochemical Society Transactions, 2014, 42, 1321-1325.	1.6	76
32	The Microtubule-Associated Protein Tau is Also Phosphorylated on Tyrosine. Journal of Alzheimer's Disease, 2009, 18, 1-9.	1.2	75
33	Kinase activities increase during the development of tauopathy in htau mice. Journal of Neurochemistry, 2007, 103, 2256-2267.	2.1	69
34	Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2016, 4, 49.	2.4	60
35	Minocycline as a potential therapeutic agent in neurodegenerative disorders characterized by protein misfolding. Prion, 2009, 3, 78-83.	0.9	59
36	Neurodegeneration as an RNA disorder. Progress in Neurobiology, 2012, 99, 293-315.	2.8	52

#	Article	IF	Citations
37	Alzheimer-related decrease in CYFIP2 links amyloid production to tau hyperphosphorylation and memory loss. Brain, 2016, 139, 2751-2765.	3.7	52
38	Membrane association and release of wild-type and pathological tau from organotypic brain slice cultures. Cell Death and Disease, 2017, 8, e2671-e2671.	2.7	50
39	Prostate-derived Sterile 20-like Kinases (PSKs/TAOKs) Phosphorylate Tau Protein and Are Activated in Tangle-bearing Neurons in Alzheimer Disease. Journal of Biological Chemistry, 2013, 288, 15418-15429.	1.6	49
40	Intracellular and Extracellular Roles for Tau in Neurodegenerative Disease. Journal of Alzheimer's Disease, 2014, 40, S37-S45.	1.2	45
41	A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies. Acta Neuropathologica Communications, 2018, 6, 37.	2.4	44
42	Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate. Brain, 2016, 139, 2290-2306.	3.7	43
43	Disruption of endoplasmic reticulum-mitochondria tethering proteins in post-mortem Alzheimer's disease brain. Neurobiology of Disease, 2020, 143, 105020.	2.1	41
44	Advances in tau-based drug discovery. Expert Opinion on Drug Discovery, 2011, 6, 797-810.	2.5	39
45	Astrocytes in Tauopathies. Frontiers in Neurology, 2020, 11, 572850.	1.1	39
46	Calpain cleavage and inactivation of the sodium calcium exchangerâ€3 occur downstream of <scp>A</scp>Î² in <scp>A</scp>lzheimer's disease. Aging Cell, 2014, 13, 49-59.	3.0	38
47	Cytokine expression during allergen-induced late nasal responses: IL-4 and IL-5 mRNA is expressed early (at 6â€ƒh) predominantly by eosinophils. Clinical and Experimental Allergy, 2000, 30, 1709-1716.	1.4	37
48	Ammonâ€™s Horn 2 (CA2) of the Hippocampus: A Long-Known Region with a New Potential Role in Neurodegeneration. Neuroscientist, 2019, 25, 167-180.	2.6	37
49	Transgenic Mouse Models of Tauopathy in Drug Discovery. CNS and Neurological Disorders - Drug Targets, 2010, 9, 403-428.	0.8	36
50	Oxysterols present in Alzheimer's disease brain induce synaptotoxicity by activating astrocytes: A major role for lipocalin-2. Redox Biology, 2021, 39, 101837.	3.9	35
51	Evidence that the presynaptic vesicle protein CSPalpha is a key player in synaptic degeneration and protection in Alzheimerâ€™s disease. Molecular Brain, 2015, 8, 6.	1.3	34
52	Organotypic Slice Cultures from Transgenic Mice as Disease Model Systems. Journal of Molecular Neuroscience, 2002, 19, 317-320.	1.1	32
53	RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies. Cellular and Molecular Life Sciences, 2007, 64, 1701-1714.	2.4	32
54	Characterisation of tau in the human and rodent enteric nervous system under physiological conditions and in tauopathy. Acta Neuropathologica Communications, 2018, 6, 65.	2.4	32

#	Article	IF	Citations
55	Preparation of organotypic brain slice cultures for the study of Alzheimerâ€™s disease. F1000Research, 2018, 7, 592.	0.8	31
56	Linking Amyloid and Tau Pathology in Alzheimer's Disease: The Role of Membrane Cholesterol in AÂ-Mediated Tau Toxicity. Journal of Neuroscience, 2009, 29, 9665-9667.	1.7	30
57	Disruption of ERâ€mitochondria tethering and signalling in <i>C9orf72</i>â€associated amyotrophic lateral sclerosis and frontotemporal dementia. Aging Cell, 2022, 21, e13549.	3.0	30
58	Kinesin light chain-1 serine-460 phosphorylation is altered in Alzheimerâ€™s disease and regulates axonal transport and processing of the amyloid precursor protein. Acta Neuropathologica Communications, 2019, 7, 200.	2.4	26
59	LMTK2 binds to kinesin light chains to mediate anterograde axonal transport of cdk5/p35 and LMTK2 levels are reduced in Alzheimerâ€™s disease brains. Acta Neuropathologica Communications, 2019, 7, 73.	2.4	21
60	Challenges in neurodegeneration research. Frontiers in Psychiatry, 2010, 1, 7.	1.3	20
61	Inhibition of glycogen synthase kinase-3 by BTA-EG4 reduces tau abnormalities in an organotypic brain slice culture model of Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 7434.	1.6	20
62	Loss of c-Jun N-terminal kinase-interacting protein-1 does not affect axonal transport of the amyloid precursor protein or AÎ² production. Human Molecular Genetics, 2013, 22, 4646-4652.	1.4	19
63	Bridging integrator 1 protein loss in Alzheimerâ€™s disease promotes synaptic tau accumulation and disrupts tau release. Brain Communications, 2020, 2, .	1.5	18
64	Tackling gaps in developing lifeâ€changing treatments for dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 241-253.	1.8	17
65	Sleep well to slow Alzheimer's progression?. Science, 2019, 363, 813-814.	6.0	17
66	Tau accumulates in Crohn's disease gut. FASEB Journal, 2020, 34, 9285-9296.	0.2	17
67	A pathogenic tau fragment compromises microtubules, disrupts insulin signaling and induces the unfolded protein response. Acta Neuropathologica Communications, 2019, 7, 2.	2.4	16
68	Synaptic Localisation of Tau. Advances in Experimental Medicine and Biology, 2019, 1184, 105-112.	0.8	16
69	Astrocytic Câ€“Xâ€“C motif chemokine ligand-1 mediates Î²-amyloid-induced synaptotoxicity. Journal of Neuroinflammation, 2021, 18, 306.	3.1	16
70	Preparation of organotypic brain slice cultures for the study of Alzheimerâ€™s disease. F1000Research, 2018, 7, 592.	0.8	14
71	Considerations for future tau-targeted therapeutics: can they deliver?. Expert Opinion on Drug Discovery, 2020, 15, 265-267.	2.5	11
72	Tau in the gut, does it really matter?. Journal of Neurochemistry, 2021, 158, 94-104.	2.1	11

#	Article	IF	Citations
73	Minocycline 200â€‰mg or 400â€‰mg versus placebo for mild Alzheimerâ€™s disease: the MADE Phase II, three-arm RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-62.	0.9	10
74	Targeting ER-Mitochondria Signaling as a Therapeutic Target for Frontotemporal Dementia and Related Amyotrophic Lateral Sclerosis. Frontiers in Cell and Developmental Biology, 2022, 10, .	1.8	9
75	Upregulation of enteric alpha-synuclein as a possible link between inflammatory bowel disease and Parkinsonâ€™s disease. Gut, 2020, 70, gutjnl-2020-323482.	6.1	2
76	HCN channelopathy couples diseaseâ€associated tau to synaptic dysfunction. Alzheimer's and Dementia, 2021, 17, e058346.	0.4	1
77	Autophagy and lysosomal defects in cells expressing diseaseâ€associated tau. Alzheimer's and Dementia, 2021, 17, e058299.	0.4	1
78	P1-293 Rapid lipid RAFT reorganisation and tyrosine phosphorylation of lipid RAFT components in response to amyloid-B peptide-treatment of primary neuronal cultures: involvement of FYN. Neurobiology of Aging, 2004, 25, S179.	1.5	0
79	P1-115: IDENTIFICATION OF THE BINDING SITE BETWEEN TAU AND FYN: CONSEQUENCES FOR TAU RELEASE?. , 2014, 10, P343-P343.		0
80	P1-116: ASTROCYTE ACTIVATION INFLUENCES THE DEVELOPMENT OF TAUOPATHY. , 2014, 10, P343-P343.		0
81	P3-054: The amyloid-binding agent bta-eg4 reduces pathological tau species in a novel organotypic 3xTg-AD brain slice culture model that recapitulates key in vivo degenerative phenotypes. , 2015, 11, P639-P639.		0
82	P1â€155: Postâ€Mortem Brain Tissue Characterisation of Inflammatory and Pathological Hallmarks of Alzheimerâ€™s Disease During Disease Progression. Alzheimer's and Dementia, 2016, 12, P462.	0.4	0
83	[P1â€"223]: FUNCTIONAL ROLES FOR TAOK KINASES IN THE DEVELOPMENT OF TAU PATHOLOGY IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P328.	0.4	0
84	[F3â€"07â€"03]: ACTIVITYâ€DEPENDENT TAU RELEASE: IMPLICATIONS FOR TAU PROPAGATION. Alzheimer's and Dementia, 2017, 13, P888.	0.4	0
85	Investigating P2X7Râ€mediated inflammatory signalling in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e047122.	0.4	0
86	Investigating the role that astrocytes play in mediating changes in synaptic health in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e047669.	0.4	0
87	Investigating the nonâ€cell autonomous role of glial chaperones in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, e058572.	0.4	0
88	Defects in the autophagy lysosomal pathway in a cell model of diseaseâ€associated tau. Alzheimer's and Dementia, 2021, 17, e051303.	0.4	0
89	Investigating astrocytes as mediators of tau spread.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e051676.	0.4	0
90	Investigating P2X7R-mediated inflammatory signalling in Alzheimer's disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e052956.	0.4	0